Trial · NCT05470491
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
NCT05470491, Phase 1, Phase 2, Recruiting, National Cancer Institute (NCI)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... Trials, record NCT05470491. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05470491
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT number
- NCT05470491
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 265 participants, estimated
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- HIV, Hematologic Malignancies
- Interventions
- RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc
- First posted
- 2022-07-22
- Last updated
- 2026-11-09
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | In phase II, avoidance rate of grade III-IV acute GVHD at day +100 | day +100 post HCT | Proportion of evaluable recipients who experience grade III-IV acute GVHD at day +100 will be reported along with 80% and 95% two-sided confidence interval |
| Primary | Determine a safe and recommended phase II dose level regimen | day +100 post HCT | Number and type of toxicities noted for participants who are evaluable |
| Secondary | Cumulative incidence of primary and secondary graft failure | day +100 and 1 year post HCT | Cumulative incidence of primary and secondary graft failure based on chimerism at day +100 and 1 year post transplant |
| Secondary | Cumulative incidence of hematopoietic recovery | day +100 | cumulative incidence of hematopoietic recovery will be based on platelet recover at day +100 |
| Secondary | Overall Survival | 1, 2, 3, 4, and 5 years post HCT | Time from transplant to death of any cause and will be determined using the Kaplan-Meier method |
| Secondary | Cumulative incidence of relapse | 1, 3, and 5 years post HCT | Cumulative incidence rates will be estimated based on disease-risk index. |
| Secondary | GVHD-free, relapse free survival (GRFS) | 1, 3, and 5 years post HCT | Time from transplant to death from any cause of other event and will be determined using the Kaplan-Meier method |
| Secondary | Cumulative incidence of acute GVHD | Day +180 and 1 year post HCT | Evaluation by all grades, grade II-IV, and grade III-IV |
| Secondary | Cumulative incidence of chronic GVHD | 1 and 2 years post HCT | Evaluation by severity of mild, moderate, and severe |
| Secondary | Progression Free Survival (PFS) | 1, 3, and 5 years post HCT | Time from transplant to disease progression and will be determined using the Kaplan-Meier method |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05470491
GET https://conductscience.org/api/trials/v1/NCT05470491/registered